Asset Management One Co. Ltd. Purchases 4,795 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Asset Management One Co. Ltd. lifted its position in shares of Inari Medical, Inc. (NASDAQ:NARI) by 7.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 66,149 shares of the company’s stock after acquiring an additional 4,795 shares during the quarter. Asset Management One Co. Ltd. owned approximately 0.11% of Inari Medical worth $3,504,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in NARI. R Squared Ltd bought a new stake in shares of Inari Medical during the fourth quarter worth $45,000. KBC Group NV raised its position in shares of Inari Medical by 39.0% during the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after acquiring an additional 498 shares during the last quarter. Covestor Ltd raised its position in shares of Inari Medical by 63.5% during the third quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after acquiring an additional 926 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Inari Medical by 66.8% during the fourth quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock worth $100,000 after acquiring an additional 786 shares during the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of Inari Medical during the third quarter worth $128,000. Institutional investors own 90.98% of the company’s stock.

Inari Medical Trading Up 0.1 %

NASDAQ:NARI opened at $79.97 on Thursday. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $79.99. The stock has a market cap of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02. The stock has a 50-day moving average price of $70.53 and a two-hundred day moving average price of $55.01.

Analyst Ratings Changes

NARI has been the subject of a number of recent research reports. Wells Fargo & Company restated an “equal weight” rating and set a $80.00 target price (up previously from $65.00) on shares of Inari Medical in a research report on Tuesday, January 7th. William Blair reaffirmed a “market perform” rating on shares of Inari Medical in a research note on Tuesday, January 7th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $80.00 price objective (up from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Piper Sandler lifted their price objective on Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 7th. Finally, Truist Financial lifted their price objective on Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Twelve investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $68.00.

Insider Buying and Selling at Inari Medical

In other news, Director William Hoffman sold 200,000 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the completion of the transaction, the director now directly owns 238,987 shares of the company’s stock, valued at $14,451,543.89. This represents a 45.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $55.29, for a total value of $165,870.00. Following the transaction, the chief executive officer now directly owns 439,310 shares of the company’s stock, valued at $24,289,449.90. This represents a 0.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 263,000 shares of company stock valued at $15,599,470. Company insiders own 10.60% of the company’s stock.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.